NCT00219375 - Study of Sivelestat Sodium Hydrate in Acute Lung Injury (ALI) Associated With Systemic Inflammatory Response Syndrome (SIRS) in Japan | Biotech Hunter

Enrollment

649

Participants

Timeline

Start Date

June 30, 2004

Primary Completion Date

July 31, 2007

Conditions

Acute Lung InjurySystemic Inflammatory Response Syndrome

Interventions

DRUG

Sivelestat sodium hydrate

0.2 mg/kg/hr continuous i.v. infusion - up to 14 days

DRUG

Sivelestat sodium hydrate

0.2 mg/kg/hr continuous i.v. infusion - up to 14 days

Trial Locations (9)

Chugoku Region Facility, Chugoku

Chubu Region Facility, Chūbu

Hokkaido Region Facility, Hokkaido

Hokuriku Regional Facility, Hokuriku

Kanto Regional Facility, Kanto

Kinki Region Facility, Kinki

Kyushu Region Facility, Kyushu

Shikoku Region Facility, Shikoku

Tohoku Region Facility, Tōhoku